DB17957ExperimentalProtein Based Therapies
RPI-MN is a detoxified or chemically modified alpha-cobratoxin with antiviral properties. Being developed by Nutra Pharma under the trade name PEPTERON, it is being investigated for the treatment of neurological...
What you can answer from here — as of April 02, 2025
Which companies are running trials of RPI-MN, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account